{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:05:40Z","timestamp":1791756340624,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008092","name":"Jinhua Science and Technology Bureau","doi-asserted-by":"publisher","award":["2020-4-149"],"award-info":[{"award-number":["2020-4-149"]}],"id":[{"id":"10.13039\/501100008092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M702833"],"award-info":[{"award-number":["2021M702833"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070409"],"award-info":[{"award-number":["82070409"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple myeloma (MM) is a prevalent hematological tumor, and recent clinical data have highlighted the significance of atrial fibrillation (AF) as a crucial complication affecting the prognosis of MM. This review aims to consolidate findings from published clinical studies, focusing on the epidemiological characteristics of AF in MM patients and the associated risks arising from MM treatments such as autologous hematopoietic stem cell transplantation, proteasome inhibitors, and immunomodulatory agents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>While existing data partially demonstrate a strong correlation between MM and AF, further clinical studies are necessary to comprehensively investigate their association. These studies should encompass various aspects, including the risk of AF resulting from MM treatment, the impact of AF-induced embolic events and heart failure on MM prognosis, as well as the influence of AF management methods like catheter ablation or left atrial appendage closure on MM prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The supplementation of future data will provide more precise guidance for managing MM patients. By incorporating information regarding AF risk associated with MM treatment and examining the effects of AF management strategies on MM prognosis, healthcare professionals can enhance their decision-making process when caring for individuals with MM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-023-00434-6","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T10:04:17Z","timestamp":1706781857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk of atrial fibrillation in patients with multiple myeloma: what is known and directions for future study"],"prefix":"10.1186","volume":"76","author":[{"given":"Ting","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4163-2309","authenticated-orcid":false,"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"3","key":"434_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"434_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D (2016) Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 43(6):676\u2013681","journal-title":"Semin Oncol"},{"issue":"5","key":"434_CR3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516\u20132520","journal-title":"Blood"},{"issue":"1","key":"434_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2009.07.006","volume":"46","author":"M Schaapveld","year":"2010","unstructured":"Schaapveld M, Visser O, Siesling S et al (2010) Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer 46(1):160\u2013169","journal-title":"Eur J Cancer"},{"issue":"6","key":"434_CR5","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/ejh.13597","volume":"106","author":"IS Sverrisd\u00f3ttir","year":"2021","unstructured":"Sverrisd\u00f3ttir IS, R\u00f6gnvaldsson S, Thorsteinsdottir S et al (2021) Comorbidities in multiple myeloma and implications on survival: a population-based study. Eur J Haematol 106(6):774\u2013782","journal-title":"Eur J Haematol"},{"issue":"1096","key":"434_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/postgradmedj-2016-134417","volume":"93","author":"TM Okwuosa","year":"2017","unstructured":"Okwuosa TM, Anzevino S, Rao R (2017) Cardiovascular disease in cancer survivors. Postgrad Med J 93(1096):82\u201390","journal-title":"Postgrad Med J"},{"issue":"3","key":"434_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","volume":"9","author":"C Plummer","year":"2019","unstructured":"Plummer C, Driessen C, Szabo Z et al (2019) Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J 9(3):26","journal-title":"Blood Cancer J"},{"issue":"5","key":"434_CR8","first-page":"e25252","volume":"14","author":"I Jackson","year":"2022","unstructured":"Jackson I, Etuk AS, Jackson N (2022) Impact of atrial fibrillation on inpatient outcomes among hospitalized patients with multiple myeloma. Cureus 14(5):e25252","journal-title":"Cureus"},{"issue":"2","key":"434_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jaccao.2021.03.006","volume":"3","author":"JP Yun","year":"2021","unstructured":"Yun JP, Choi EK, Han KD et al (2021) Risk of atrial fibrillation according to cancer type: a nationwide population-based study. JACC CardioOncol 3(2):221\u2013232","journal-title":"JACC CardioOncol"},{"issue":"5","key":"434_CR10","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/joa3.12589","volume":"37","author":"MZ Khan","year":"2021","unstructured":"Khan MZ, Gupta A, Patel K et al (2021) Association of atrial fibrillation and various cancer subtypes. J Arrhythm 37(5):1205\u20131214","journal-title":"J Arrhythm"},{"key":"434_CR11","doi-asserted-by":"publisher","first-page":"753918","DOI":"10.3389\/fcvm.2021.753918","volume":"8","author":"Y Li","year":"2021","unstructured":"Li Y, Tang M, Zhong L et al (2021) Incidence of arrhythmias and their prognostic value in patients with multiple myeloma. Front Cardiovasc Med 8:753918","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"434_CR12","first-page":"480","volume":"61","author":"Chinese Hematology Association, Chinese Society of Hematology","year":"2022","unstructured":"Chinese Hematology Association, Chinese Society of Hematology (2022) Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision). Zhonghua Nei Ke Za Zhi 61(5):480\u2013487","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"4","key":"434_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/cncr.28444","volume":"120","author":"SH Armenian","year":"2014","unstructured":"Armenian SH, Chow EJ (2014) Cardiovascular disease in survivors of hematopoietic cell transplantation. Cancer 120(4):469\u2013479","journal-title":"Cancer"},{"issue":"10","key":"434_CR14","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","volume":"110","author":"S Bhatia","year":"2007","unstructured":"Bhatia S, Francisco L, Carter A et al (2007) Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 110(10):3784\u20133792","journal-title":"Blood"},{"issue":"10","key":"434_CR15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.bbmt.2007.06.003","volume":"13","author":"NS Majhail","year":"2007","unstructured":"Majhail NS, Ness KK, Burns LJ et al (2007) Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant 13(10):1153\u20131159","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"434_CR16","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/bmt.2015.127","volume":"50","author":"ES Tonorezos","year":"2015","unstructured":"Tonorezos ES, Stillwell EE, Calloway JJ et al (2015) Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplant 50(9):1212\u20131216","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"434_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1753944712464102","volume":"6","author":"RK Sureddi","year":"2012","unstructured":"Sureddi RK, Amani F, Hebbar P et al (2012) Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors. Ther Adv Cardiovasc Dis 6(6):229\u2013236","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"8","key":"434_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ajh.21459","volume":"84","author":"K Fatema","year":"2009","unstructured":"Fatema K, Gertz MA, Barnes ME et al (2009) Acute weight gain and diastolic dysfunction as a potent risk complex for post stem cell transplant atrial fibrillation. Am J Hematol 84(8):499\u2013503","journal-title":"Am J Hematol"},{"issue":"19","key":"434_CR19","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875\u20131883","journal-title":"N Engl J Med"},{"issue":"18","key":"434_CR20","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1182\/blood-2009-08-238196","volume":"115","author":"J Blad\u00e9","year":"2010","unstructured":"Blad\u00e9 J, Rosi\u00f1ol L, Cibeira MT et al (2010) Hematopoietic stem cell transplantation for multiple myeloma beyond. Blood 115(18):3655\u20133663","journal-title":"Blood"},{"issue":"3","key":"434_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M et al (2002) Comparison of 200 mg\/m(2) melphalan and 8 Gy total body irradiation plus 140 mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du My\u00e9lome 9502 randomized trial. Blood 99(3):731\u2013735","journal-title":"Blood"},{"issue":"10","key":"434_CR22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/sj.bmt.1701763","volume":"23","author":"P Moreau","year":"1999","unstructured":"Moreau P, Milpied N, Mah\u00e9 VB et al (1999) Melphalan 220 mg\/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 23(10):1003\u20131006","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"434_CR23","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/sj.bmt.1704946","volume":"35","author":"A Spencer","year":"2005","unstructured":"Spencer A, Horvath N, Gibson J et al (2005) Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 35(10):971\u2013977","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"434_CR24","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/annonc\/mdl332","volume":"18","author":"N Blijlevens","year":"2007","unstructured":"Blijlevens N, Sonis S (2007) Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy- induced mucositis. Ann Oncol 18(5):817\u2013826","journal-title":"Ann Oncol"},{"issue":"25","key":"434_CR25","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1056\/NEJMoa040125","volume":"351","author":"R Spielberger","year":"2004","unstructured":"Spielberger R, Stiff P, Bensinger W et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351(25):2590\u20132598","journal-title":"N Engl J Med"},{"issue":"1","key":"434_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bbmt.2012.08.003","volume":"19","author":"MH Abidi","year":"2013","unstructured":"Abidi MH, Agarwal R, Tageja N et al (2013) A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Biol Blood Marrow Transplant 19(1):56\u201361","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"434_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1054\/bjoc.2001.1928","volume":"85","author":"B Sirohi","year":"2001","unstructured":"Sirohi B, Powles R, Kulkarni S et al (2001) Glomerular filtration rate prior to high-dose melphalan 200 mg\/m(2) as a surrogate marker of outcome in patients with myeloma. Br J Cancer 85(3):325\u2013332","journal-title":"Br J Cancer"},{"issue":"1","key":"434_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","volume":"75","author":"LM Knudsen","year":"2005","unstructured":"Knudsen LM, Nielsen B, Gimsing P et al (2005) Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 75(1):27\u201333","journal-title":"Eur J Haematol"},{"issue":"4","key":"434_CR29","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros A, Barlogie B, Siegel E et al (2001) Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 114(4):822\u2013829","journal-title":"Br J Haematol"},{"issue":"9","key":"434_CR30","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.bbmt.2012.03.010","volume":"18","author":"MH Abidi","year":"2012","unstructured":"Abidi MH, Agarwal R, Ayash L et al (2012) Melphalan 180\u00a0mg\/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL\/min\/1.73\u00a0m2 or lower with use of palifermin for cytoprotection: results of a phase I trial. Biol Blood Marrow Transplant 18(9):1455\u20131461","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"434_CR31","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1080\/10428190500235884","volume":"46","author":"LR Mileshkin","year":"2005","unstructured":"Mileshkin LR, Seymour JF, Wolf MM et al (2005) Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma 46(11):1575\u20131579","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"434_CR32","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"11","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 11(5):2516\u20132520","journal-title":"Blood"},{"key":"434_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-010-0104-8","volume":"28","author":"APG Rodr\u00edguez","year":"2011","unstructured":"Rodr\u00edguez APG (2011) Management of the adverse effects of lenalidomide in multiple myeloma. Adv Ther 28:1\u201310","journal-title":"Adv Ther"},{"issue":"10","key":"434_CR34","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1634\/theoncologist.2008-0077","volume":"13","author":"M Hazarika","year":"2008","unstructured":"Hazarika M, Rock E, Williams G et al (2008) Lenalidomide in combination which dexamethasone for the treatment of multiple myeloma after one prior therapy. Oncologist 13(10):1120\u20131127","journal-title":"Oncologist"},{"key":"434_CR35","doi-asserted-by":"publisher","first-page":"739044","DOI":"10.3389\/fcvm.2022.739044","volume":"9","author":"J Ahmad","year":"2022","unstructured":"Ahmad J, Thurlapati A, Thotamgari S et al (2022) Anti-cancer drugs associated atrial fibrillation\u2014an analysis of real-world pharmacovigilance data. Front Cardiovasc Med 9:739044","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"434_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/2040620716652862","volume":"7","author":"H Magen","year":"2016","unstructured":"Magen H, Muchtar E (2016) Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol 7(4):187\u2013195","journal-title":"Ther Adv Hematol"},{"issue":"Spec Feature","key":"434_CR37","first-page":"102","volume":"9","author":"LA Raedler","year":"2016","unstructured":"Raedler LA (2016) Ninlaro (Ixazomib): first oral proteasome inhibitor approved for the treatment of patients with relapsed or refractory multiple myeloma. Am Health Drug Benefits 9(Spec Feature):102\u2013105","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"434_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","volume":"9","author":"L Sanchez","year":"2016","unstructured":"Sanchez L, Wang Y, Siegel DS et al (2016) Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol 9(1):51","journal-title":"J Hematol Oncol"},{"issue":"21","key":"434_CR39","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","volume":"21","author":"JP Laubach","year":"2015","unstructured":"Laubach JP, Moreau P, San-Miguel JF et al (2015) Panobinostat for the treatment of multiple myeloma. Clin Cancer Res 21(21):4767\u20134773","journal-title":"Clin Cancer Res"},{"key":"434_CR40","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.2147\/DDDT.S267404","volume":"15","author":"M Offidani","year":"2021","unstructured":"Offidani M, Corvatta L, Mor\u00e8 S et al (2021) Belantamab mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety. Drug Des Devel Ther 15:2401\u20132415","journal-title":"Drug Des Devel Ther"},{"key":"434_CR41","first-page":"169","volume":"13","author":"NS Joseph","year":"2021","unstructured":"Joseph NS, Tai YT, Anderson KC et al (2021) Novel approaches to treating relapsed and refractory multiple myeloma with a focus on recent approvals of belantamab mafodotin and selinexor. Clin Pharmacol 13:169\u2013180","journal-title":"Clin Pharmacol"},{"key":"434_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15499","author":"Z Al-Yafeai","year":"2022","unstructured":"Al-Yafeai Z, Ghoweba M, Ananthaneni A et al (2022) Cardiovascular complications of modern multiple myeloma therapy: a pharmacovigilance study. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.15499","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"434_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","volume":"42","author":"RR Shah","year":"2019","unstructured":"Shah RR (2019) Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology. Drug Saf 42(2):235\u2013245","journal-title":"Drug Saf"},{"issue":"22","key":"434_CR44","doi-asserted-by":"publisher","first-page":"6841","DOI":"10.1158\/1078-0432.CCR-09-0547","volume":"15","author":"J Arts","year":"2009","unstructured":"Arts J, King P, Mari\u00ebn A et al (2009) JNJ-26481585, a novel \u201csecond-generation\u201d oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 15(22):6841\u20136851","journal-title":"Clin Cancer Res"},{"issue":"10","key":"434_CR45","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1038\/leu.2009.121","volume":"23","author":"S Deleu","year":"2009","unstructured":"Deleu S, Lemaire M, Arts J et al (2009) The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia 23(10):1894\u20131903","journal-title":"Leukemia"},{"issue":"4","key":"434_CR46","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2141.2010.08126.x","volume":"149","author":"T St\u00fchmer","year":"2010","unstructured":"St\u00fchmer T, Arts J, Chatterjee M et al (2010) Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. Br J Haematol 149(4):529\u2013536","journal-title":"Br J Haematol"},{"issue":"13","key":"434_CR47","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-08-4472","volume":"69","author":"S Deleu","year":"2009","unstructured":"Deleu S, Lemaire M, Arts J et al (2009) Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res 69(13):5307\u20135311","journal-title":"Cancer Res"},{"issue":"7","key":"434_CR48","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.3109\/10428194.2015.1117611","volume":"57","author":"P Moreau","year":"2016","unstructured":"Moreau P, Facon T, Touzeau C et al (2016) Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma. Leuk Lymphoma 57(7):1546\u20131559","journal-title":"Leuk Lymphoma"},{"issue":"6917","key":"434_CR49","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860\u2013867","journal-title":"Nature"},{"issue":"3","key":"434_CR50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/aam.aam_56_18","volume":"18","author":"N Singh","year":"2019","unstructured":"Singh N, Baby D, Rajguru JP et al (2019) Inflammation and cancer. Ann Afr Med 18(3):121\u2013126","journal-title":"Ann Afr Med"},{"issue":"1","key":"434_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI (2019) Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51(1):27\u201341","journal-title":"Immunity"},{"issue":"5","key":"434_CR52","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1160\/TH16-11-0825","volume":"117","author":"V Allan","year":"2017","unstructured":"Allan V, Honarbakhsh S, Casas JP et al (2017) Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost 117(5):837\u2013850","journal-title":"Thromb Haemost"},{"issue":"21","key":"434_CR53","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.jacc.2007.06.054","volume":"50","author":"TT Issac","year":"2007","unstructured":"Issac TT, Dokainish H, Lakkis NM (2007) Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 50(21):2021\u20132028","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"434_CR54","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/eurheartj\/ehi350","volume":"26","author":"MDM Engelmann","year":"2005","unstructured":"Engelmann MDM, Svendsen JH (2005) Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 26(20):2083\u20132092","journal-title":"Eur Heart J"},{"issue":"1","key":"434_CR55","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-019-6314-9","volume":"19","author":"CB Jakobsen","year":"2019","unstructured":"Jakobsen CB, Lamberts M, Carlson N et al (2019) Incidence of atrial fibrillation in different major cancer subtypes: a nationwide population-based 12 year follow up study. BMC Cancer 19(1):1105","journal-title":"BMC Cancer"},{"issue":"5","key":"434_CR56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42(5):373\u2013498","journal-title":"Eur Heart J"},{"issue":"9","key":"434_CR57","doi-asserted-by":"publisher","first-page":"euad263","DOI":"10.1093\/europace\/euad263","volume":"25","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, Munir MB, Krishan S et al (2023) Outcomes and readmissions in patients with cancer undergoing catheter ablation for atrial fibrillation. Europace 25(9):euad263","journal-title":"Europace"},{"key":"434_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-023-01677-8","author":"TA Costa","year":"2023","unstructured":"Costa TA, Felix N, Clemente M et al (2023) Safety and efficacy of catheter ablation for atrial fibrillation in cancer survivors: a systematic review and meta-analysis. J Interv Card Electrophysiol. https:\/\/doi.org\/10.1007\/s10840-023-01677-8","journal-title":"J Interv Card Electrophysiol"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-023-00434-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-023-00434-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-023-00434-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T13:12:20Z","timestamp":1706793140000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-023-00434-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1186\/s43044-023-00434-6","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"18 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed the manuscript and agreed for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}